ClinicalTrials.Veeva

Menu

A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

P

Pamlab

Status

Completed

Conditions

Preeclampsia
Anemia in Pregnancy

Treatments

Other: Neevo® (a medical food)
Other: Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)

Study type

Observational

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

This study is a multi-site, retrospective chart review to determine the effect of Neevo® or Neevo®DHA (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy. Neevo® is a prescription medical food indicated for the dietary management of women under a doctor's care who face high risk pregnancies, older overactive bladder (OB) patients and patients unable to fully metabolize folic acid. Data will be collected from existing patient charts of subjects administered Neevo® or Neevo®DHA daily compared to subjects administered a prenatal vitamin daily.

Enrollment

100 patients

Sex

Female

Ages

21 to 39 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Pregnant females, age 21-39, who received either Neevo®/Neevo®DHA or another standard prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and ≤12mcg vitamin B12).
  • Clinical diagnosis of pregnancy must have been made at ≤12 weeks of pregnancy and on or after January 1, 2008 and delivery must have occurred on or before December 31, 2009.
  • Subjects must have been compliant in taking Neevo DHA or other prenatal vitamin.

Exclusion criteria

  • Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are L-methylfolate-containing prenatal vitamins.
  • The following supplements within 2 months prior to randomization; 100mg vitamin C, B12 injection >10mg of B6; >32mg Iron; >1.2mg of folate; an L- methylfolate product that is not a prenatal vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF, Metanx®, Neevo®, Neevo®DHA, Deplin®, Cerefolin®, or CerefolinNAC®.
  • History of any anemia other than iron deficiency anemia or leukemia.
  • Blood transfusion in the 4 months prior to diagnosis of pregnancy.

Trial design

100 participants in 2 patient groups

Arm #1 (Test group)
Description:
50 subjects administered Neevo® or Neevo®DHA daily
Treatment:
Other: Neevo® (a medical food)
Arm #2 (Control group)
Description:
50 subjects administered a prenatal vitamin daily
Treatment:
Other: Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems